ClinicalTrials.gg
Active, not recruitingNCT03390686Updated May 31, 2025

A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients

A Phase 3 interventional study of Bevacizumab and HD204 in Lung Cancer and Non-small Cell Lung Cancer, sponsored by Prestige Biopharma Limited. Active, not recruiting at 18 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: Lung NeoplasmsReclassifiedWhy we changed it
Registry
Lung Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's listed conditions name Carcinoma, Non-Small-Cell Lung, a narrower term within Lung Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Prestige Biopharma Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
650
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Carcinoma, Non-Small-Cell Lung with a site in Georgia — 9 open to participants now, 31 under way, 14 of them phase 3. Carcinoma, Non-Small-Cell Lung · Georgia.

Enrollment
14th of 54
650 · median 222
Started
2019
with 3 others
Phase 3
25 of 54
2 open now
Primary completion
2024-07
later than 0 of 30 live
Registered
11th of 54
by date

Among the 54 studies in Carcinoma, Non-Small-Cell Lung with a site in Georgia, this one is the 14th largest by enrollment, is one of 4 that started in 2019, is one of 25 in phase 3, reaches primary completion later than 0 of the 30 other live ones, and was the 11th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 54 studies in Carcinoma, Non-Small-Cell Lung with a site in Georgia are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Georgia have not opened yet or have stopped. Only those recruiting at a site in Georgia →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Carcinoma, Non-Small-Cell Lung with a site in Georgia, or all of them as a file.
02

Study summary

In the SAMSON-2 study, the proposed biosimilar HD204 will be compared to its reference product EU-licensed Avastin®. The aim of the study is to demonstrate equivalence of HD204 and EU-licensed Avastin® in terms of efficacy, safety, pharmacokinetics and immunogenicity.

Read the detailed description

This is a randomised, double-blind, parallel group, equivalence, multicentre Phase III study in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC).

Standard efficacy parameters, safety profiles, pharmacokinetics and immunogenicity will be compared between HD204 and bevacizumab.

03

Conditions studied

  • Lung Cancer
  • Non-small Cell Lung Cancer

Browse trials for

04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's enrollment of 650 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Prestige Biopharma Limited is the lead sponsor of 6 studies on the registry; none are open to participants now.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18 years
  • performance status of 0-1
  • -confirmed or recurrent non-squamous non-small cell lung cancer
  • At least one according to v1.1.
  • Able to receive bevacizumab, carboplatin and paclitaxel based on adequate laboratory and clinical parameters

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of small cell carcinoma of the lung or squamous cell carcinoma
  • Sensitizing EGFR mutations or ALK rearrangements
  • Increased risk of bleeding determined by investigator based on radiographic / clinical findings
  • History of systemic chemotherapy administered in the setting for or recurrent disease of NSCLC.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
650 participants (actual)

Study arms

  • Experimental
    HD204 (Bevacizumab biosimilar)

    HD204 + Carboplatin/Paclitaxel

    Drug: HD204 · Drug: Carboplatin · Drug: Paclitaxel

  • Active comparator
    Avastin (Bevacizumab)

    Avastin® + Carboplatin/Paclitaxel

    Drug: Bevacizumab · Drug: Carboplatin · Drug: Paclitaxel

Interventions

  • 15 mg/kg IV every 3 weeks on Day 1

    Also known as: Avastin

  • DrugHD204

    15 mg/kg IV every 3 weeks on Day 1

    Also known as: Bevacizumab

  • Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles

  • Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles

    Also known as: Taxol

07

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) at Week 18

    Percent patients within each treatment group who achieved complete response (CR) or partial response (PR) by the time of the Week 18 efficacy analysis in accordance with the RECIST 1.1. as assessed by CIR.

    Time frame: 18 weeks from randomization

Secondary outcomes

  1. ORR at Week 6

    Response at Week 6 will be evaluated by CIR to show the pattern of response

    Time frame: 6 weeks from randomization

  2. ORR at Week 12

    Response at Week 12 will be evaluated by CIR to show the pattern of response

    Time frame: 12 weeks from randomization

  3. ORR at Week 18 adjusted on dose intensity

    To compare ORR at Week 18 adjusted on dose intensity between treatment groups

    Time frame: 18 weeks from randomization

  4. Duration of Response

    DoR in subjects with response from documented tumour response until disease progression up to 12 months from randomisation of the last subject

    Time frame: from documented tumour response until disease progression up to 12 months from randomisation

  5. Progression Free Survival

    PFS from the date of randomisation to the date of disease progression or death up to 12 months from randomisation

    Time frame: From the date of randomisation to the date of disease progression or death up to 12 months from randomisation of the last subject

  6. Overall Survival (OS)

    OS defined as the time from Day 1 of therapy until death from any cause

    Time frame: From the date of randomisation to the date of death up to 12 months from randomisation

  7. Change in tumour burden from baseline

    Measured by the sum of longest diameters (SLD) of the target lesions

    Time frame: Up to 52 weeks from baseline

  8. Incidence of Treatment-related Adverse Events using CTCAE v5.0

    After the end of treatment (EOT) visit, SAEs should be reported to the Sponsor if the Investigator becomes aware of them.

    Time frame: From signing the ICF until 1 month after the last administration of treatment, i.e., up to 52 weeks

  9. Anti-Drug Antibodies (Immunogenicity)

    Incidence of anti-drug (bevacizumab) antibodies (ADA)

    Time frame: Up to 52 weeks (at Baseline; end of Cycle 4 [pre-dose in cycle 5]; end of Cycle 7 [pre-dose in cycle 8]; and at EOT)

  10. Neutralizing Antibodies (Immunogenicity)

    Incidence of anti-drug (bevacizumab) antibodies (ADA) - neutralizing antibodies (NAb)

    Time frame: Up to 52 weeks (at Baseline; end of Cycle 4 [predose in cycle 5]; end of Cycle 7 [predose in cycle 8]; and at EOT)

  11. Trough Level [Ctrough] (Pharmacokinetics)

    Concentration observed 19 to 23 days after study drug administration

    Time frame: Up to 52 weeks (end of Cycle 1 [predose of Cycle 2], end of Cycle 3 [predose of Cycle 4], end of Cycle 5 [predose of Cycle 6] and EOT)

  12. Maximum Plasma Concentration [Cmax] (Pharmacokinetics)

    Cmax at selected cycles

    Time frame: Up to 21 weeks (Cycle 2 ,4 and 6. Each cycle is 21 days.)

  13. Area under the concentration-time curve from 0 hr to time t [AUC0-t] (Pharmacokinetics)

    AUC0-t at selected cycles

    Time frame: Up to 21 weeks (Cycle 2 ,4 and 6. Each cycle is 21 days.)

08

Study locations

18 sites
  • Alexandrov Cancer Center
    Minsk, Minsk City 223040, Belarus
  • MHAT "Dr. Tota Venkova", AD
    Gabrovo, 5300, Bulgaria
  • CHC Osijek
    Osijek, Osijecko-baranjska 31000, Croatia
  • LTD "High Technology Hospital Medcenter"
    Batumi, 6010, Georgia
  • Institute of Clinical Oncology
    Tbilisi, 0159, Georgia
  • Interbalkan Hospital
    Thessaloniki, Asklipiou 10 57001, Greece
  • Tudogyogyintezet Torokbalint
    Törökbálint, 2045, Hungary
  • HCG Manavata Cancer Centre
    Nashik, Maharashtra 422002, India
  • Riga East University Hospital Latvian Oncology centre
    Riga, Latvia
  • HRPZ II
    Kota Bharu, Kelantan 15586, Malaysia
  • Asian Hospital and Medical Center
    City of Muntinlupa, 1781, Philippines
  • Magodend Szpital Elblaska
    Warsaw, 01748, Poland
  • MEDSI
    Moscow, Otradnoye 143422, Russia
  • IPD of Vojvodina
    Kamenitz, 21204, Serbia
  • Nemocnica na okraji mesta, n.o.
    Partizánske, 95801, Slovakia
  • Maharaj Nakorn Chiang Mai
    Chiang Mai, Muang 50200, Thailand
  • Acibadem Adana Hospital
    Adana, 01060, Turkey (Türkiye)
  • Oncology Dispensary
    Odesa, 65055, Ukraine
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Jul 2024, 55 months.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 55 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2017
First posted
Jan 4, 2018
StartActual
Nov 15, 2019
Primary completionActual
Jul 1, 2024
CompletionEst.
Dec 2025
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03390686
Lead sponsor
Prestige Biopharma Limited
Responsible party
Sponsor
First posted
Jan 4, 2018
Start date
Nov 15, 2019
Primary completion
Jul 1, 2024
Completion
Dec 2025 (estimated)
Last update
May 31, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion